QUEBEC CITY, QUEBEC--(Marketwire - June 2, 2008) - Medicago Inc. (TSX VENTURE:MDG) (the "Company"), today announced that Mr. Andy Sheldon, President and CEO, will participate in a panel discussion entitled "Addressing the limited global capacity in producing pandemic and seasonal flu vaccines" at the World Vaccine Congress Asia 2008. The conference will be held at the Grand Hyatt Singapore, Singapore, from June 2-5, 2008.

During the session, Mr. Sheldon and other leading vaccine experts will describe what are the technical manufacturing challenges and strategies to increase vaccine production capacity, as well as discuss the continuous progress to improve vaccine production technology and production of vaccines for broader protection.

World Vaccine Congress Asia 2008 is a meeting where vaccine buyers and sellers, health authorities, financing institutions, regulators, vaccine producers and manufacturers, technology providers and other stakeholders come together to discuss industry trend, market and partnership opportunities, new vaccines and new technology innovations across Asia.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.